Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | SF295; SF.295; SF 295 |
| Species | Human |
| Cat.No | ABC-TC500S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Storage | Liquid Nitrogen |
| Product Type | Human Nerve Tumors Cell Lines |
SF-295 is a human glioblastoma cell line derived from a left frontal lobe tumor of a 67-year-old Caucasian female patient. These cells exhibit glial-like morphology and are hypertriploid, with a near-pentaploid chromosome number ranging from 104 to 126. They are homozygous for mutations in tumor suppressor genes PTEN and TP53 and possess a TERT promoter mutation (C228T), commonly associated with glioblastoma multiforme (GBM). SF-295 cells lack expression of glial markers GFAP and glutamine synthetase but express neurofibromin-1 (NF1). In vivo studies have shown that SF-295 cells are non-tumorigenic in athymic mice. This cell line has been extensively utilized in preclinical research, including studies on chemotherapeutic agents like temozolomide and BCNU, where it demonstrated significant tumor growth delay and synergistic effects when used in combination therapies. SF-295 is also part of the NCI-60 cancer cell line panel, making it a valuable model for investigating GBM biology and therapeutic responses.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The SF-295 cell line has broad utility in brain cancer research, particularly focused on glioblastoma multiforme (GBM), the most aggressive and malignant form of brain cancer. It serves as a standard brain tumor model in various cell line panel projects, making it invaluable in contemporary research. SF-295 is highly utilized in studies investigating chemotherapeutic treatments for glioblastoma, providing a valuable cellular model for assessing the impact of drugs and molecular modulators on glioblastomas. Through these applications, SF-295 contributes significantly to advancing our understanding and developing new treatment strategies for this devastating disease.
